Literature DB >> 15660466

Arthritis and employment research: where are we? Where do we need to go?

Diane Lacaille1.   

Abstract

Studies of work disability among individuals with arthritis reveal that loss of employment is a common, important, and costly problem. Arthritis and musculoskeletal conditions are the leading cause of longterm work disability in Canada and the US, with an estimated yearly cost of 13.7 billion dollars in Canada. In rheumatoid arthritis, reported rates of work disability are remarkably high, ranging from 32% to 50% 10 years after RA onset, and increasing to 50% to 90% after 30 years. Studies have shown that work disability starts early in the course of RA, emphasizing the need for early intervention. To date, research in the area of arthritis and employment has mostly focused on measuring the extent of the problem and on identifying predictors of work loss. Despite the importance of the problem, there has been little intervention research assessing the effectiveness of medical treatment and few interventions specifically aimed at employment, reducing work loss, or improving ability to work. Research needed includes evaluating the effect of current therapies on employment outcomes, and studying interventions specifically aimed at employment, as well as addressing methodological issues in employment research.

Entities:  

Mesh:

Year:  2005        PMID: 15660466

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  10 in total

1.  Systemic lupus erythematosus in a multiethnic US cohort LUMINA (XLI): factors predictive of self-reported work disability.

Authors:  A M Bertoli; M Fernández; G S Alarcón; L M Vilá; J D Reveille
Journal:  Ann Rheum Dis       Date:  2006-06-30       Impact factor: 19.103

Review 2.  The value of early intervention in RA--a window of opportunity.

Authors:  Ferdinand Breedveld
Journal:  Clin Rheumatol       Date:  2011-02-25       Impact factor: 2.980

3.  Work loss and work entry among persons with systemic lupus erythematosus: comparisons with a national matched sample.

Authors:  Edward Yelin; Chris Tonner; Laura Trupin; Pantelis Panopalis; Jinoos Yazdany; Laura Julian; Patricia Katz; Lindsey A Criswell
Journal:  Arthritis Rheum       Date:  2009-02-15

4.  Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol.

Authors:  Johanna M Hazes; Peter Taylor; Vibeke Strand; Oana Purcaru; Geoffroy Coteur; Philip Mease
Journal:  Rheumatology (Oxford)       Date:  2010-06-14       Impact factor: 7.580

Review 5.  Photodynamic therapy induces an immune response against a bacterial pathogen.

Authors:  Ying-Ying Huang; Masamitsu Tanaka; Daniela Vecchio; Maria Garcia-Diaz; Julie Chang; Yuji Morimoto; Michael R Hamblin
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

6.  Work disability among two cohorts of women with recent-onset rheumatoid arthritis: a survival analysis.

Authors:  S Reisine; J Fifield; S Walsh; D Dauser
Journal:  Arthritis Rheum       Date:  2007-04-15

7.  Not better but quite good: effects on work loss of combination treatment for rheumatoid arthritis with and without biological agents.

Authors:  Edward Yelin
Journal:  JAMA Intern Med       Date:  2013-08-12       Impact factor: 21.873

Review 8.  The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life.

Authors:  Roy Fleischmann
Journal:  Open Access Rheumatol       Date:  2009-07-13

Review 9.  Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders.

Authors:  Akira Yuasa; Naohiro Yonemoto; Kazumasa Kamei; Toshiaki Murofushi; Michael LoPresti; Ankush Taneja; Jake Horgan; Shunya Ikeda
Journal:  Adv Ther       Date:  2022-10-07       Impact factor: 4.070

10.  Work disability in scleroderma is greater than in rheumatoid arthritis and is predicted by high HAQ scores.

Authors:  Janine M Ouimet; Janet E Pope; Iris Gutmanis; John Koval
Journal:  Open Rheumatol J       Date:  2008-09-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.